Status:
RECRUITING
Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease
Lead Sponsor:
University Hospital Schleswig-Holstein
Collaborating Sponsors:
University of Kiel
Conditions:
Parkinson Disease
Nutritional and Metabolic Diseases
Eligibility:
All Genders
50-80 years
Brief Summary
Many patients with Parkinson's Disease (PD) report an increased consumption of fast-acting sugars. This tendency to consume sweet, high-sugar foods occurs in some patients even before the onset of car...
Eligibility Criteria
Inclusion
- Diagnosis of Parkinson's Disease, stage Hoehn \& Yahr 1.5-3
- Ability to pause antiparkinsonian medication in the morning without relevant impairment
- Capacity to give consent (determined in doubt by two independent neurologists, MOCA ≥18) and written informed consent.
- Patients are between 50 and 80 years of age, with exceptions for a maximum of 5 additional patients enrolled per group
- For stratification into patients with and without sweet craving, a 3-day dietary protocol should be completed once by the patients
- Group I: increased hunger for sweets.
- Group II: no increased hunger for sweets.
- For the stratification into patients with and without increased hunger for sweets, participants are asked to answer the following questions:
- Do you have sudden attacks of cravings for sweets?
- Would you say that your consumption of sweet food has increased in recent years?
- Would you describe your consumption of sugary food as increased or excessive?
- If one of the questions is answered with yes, participants will be assigned to group I, if all questions are answered with no, participants will be assigned to group II.
Exclusion
- Other significant neurological diseases primarily affecting the central nervous system (e.g., multiple sclerosis)
- Diagnosis of diabetes mellitus or prediabetes
- Use of medications that affect glucose metabolism, such as antidiabetics, glucocorticoids, ciclosporin, tacrolimus, sirolimus, beta-blockers, thiazide diuretics, beta-2 adrenoreceptor agonists, theophylline, Clozapine, olanzapine, paliperidone, quetiapine, risperidone, tricyclic antidepressants, mirtazapine, mianserin, carbamazepine, gabapentin, pregabalin, valproic acid, lithium, antiretroviral drugs, statins
- cardiac or brain pacemakers
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05998772
Start Date
September 1 2023
End Date
December 1 2025
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department for Neurology, University of Kiel
Kiel, Germany, 24118